About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Microbiome Research’s group seeks to investigate the role of the microbiota in health and disease. Its secondary objectives include developing molecular as well as bioinformatics tools to characterize the microbiome structure and function, discovering micro-biomarkers for diagnosis and prognosis, investigating how fecal microbiota transplantation could be used as a therapeutic strategy, and evaluating the impact of diet on the gut microbial ecosystem The Microbiome Lab is a multidisciplinary team, composed of molecular biologists, bioinformaticians, and physicians. The group tackles several clinical fields including inflammatory bowel diseases, diabetes, liver diseases, pre-term birth, and critical illness.
IP: Chaysavanh Manichanh
IP: Chaysavanh Manichanh Collaborators: Luis Fernando Mayorga Ayala Funding agency: Instituto de Salud Carlos III Funding: 65000 Reference: CM21/00198 Duration: 01/01/2022 - 31/12/2023
IP: Chaysavanh Manichanh Collaborators: Zaida Soler Luque Funding agency: Instituto de Salud Carlos III Funding: 119567 Reference: FI21/00262 Duration: 01/01/2022 - 31/12/2025
IP: Chaysavanh Manichanh Collaborators: Claudia Maria Herrera de Guise, Natalia Borruel Sainz, Francesc Casellas Jordá, Encarna Varela Castro, Luis Fernando Mayorga Ayala, Francisca Yañez Araya, Zixuan Xie Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI20/00130 Duration: 01/01/2021 - 31/12/2023
IP: Chaysavanh Manichanh Collaborators: Claudia Maria Herrera de Guise, Francesc Casellas Jordá Funding agency: Instituto de Salud Carlos III Funding: 147620 Reference: PI17/00614 Duration: 01/01/2018 - 30/06/2022
IP: Chaysavanh Manichanh Collaborators: Zixuan Xie Funding agency: EUROPEAN COMMISSION Funding: 236504.88 Reference: FUNHOMIC_H2020MSCA-ITN2018 Duration: 01/01/2019 - 31/12/2022
IP: Chaysavanh Manichanh Collaborators: Judit Álvarez González Funding agency: Instituto de Salud Carlos III Funding: 101250 Reference: CPII18/00006 Duration: 01/01/2019 - 31/12/2021
IP: Chaysavanh Manichanh Collaborators: - Funding agency: The Crohn's & Colitis Foundation of America Funding: 170147.63 Reference: MIPREDIP_CHRON2017 Duration: 01/02/2018 - 30/06/2021
IP: Chaysavanh Manichanh Collaborators: - Funding agency: Fundació Institut de Recerca HUVH Funding: 46800 Reference: PRED-VHIR-2015-33 Duration: 01/03/2016 - 28/02/2019
IP: Chaysavanh Manichanh Collaborators: - Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 103604.66 Reference: SLT002/16/00367 Duration: 06/04/2017 - 31/12/2019
IP: Chaysavanh Manichanh Collaborators: Claudia Maria Herrera de Guise, Natalia Borruel Sainz, Francisco Guarner Aguilar, Francesc Casellas Jordá, Virginia Robles Alonso, Encarna Varela Castro Funding agency: Instituto de Salud Carlos III Funding: 254402.5 Reference: PI14/00764 Duration: 01/01/2015 - 30/06/2018
IP: Chaysavanh Manichanh Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 145080 Reference: INCOMED - FELLOW 2 Duration: 18/08/2014 - 17/08/2017
IP: Chaysavanh Manichanh Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 121500 Reference: CP13/00181 Duration: 01/01/2014 - 31/03/2017
IP: Chaysavanh Manichanh Collaborators: Francisco Guarner Aguilar, Ana María Accarino Garaventa, Encarna Varela Castro Funding agency: Instituto de Salud Carlos III Funding: 191180 Reference: PI10/00902 Duration: 01/01/2011 - 30/06/2014
PMID: 35764931 Journal: BMC GASTROENTEROLOGY Year: 2022 Reference: BMC Gastroenterol. 2022 Jun 28;22(1):320. doi: 10.1186/s12876-022-02392-w. Impact factor: 3.067 Publication type: Paper in international publication Authors: Batista, Lissette; Robles, Virginia; Manichanh, Chaysavanh; Ruiz, Laura; Pinsach, Ferran; Guarner, Francisco; Fernandez-Banares, Fernando; Guagnozzi, Danila et al. DOI: 10.1186/s12876-022-02392-w
The composition of gut microbiota is unique, like our fingerprints.
FunHoMic integrates experts in fungal pathogenesis, immunology, microbial ecology and "omics" technologies to train 13 researchers to identify biomarkers related to the risk of infection by fungi such as Candida.
The quantification of the gut microbiota, combined with clinical data, would be useful to facilitate the correct diagnosis of patients and offer them the appropriate treatment for their pathology and also to prevent the appearance of flares.
We are looking for approximately 1,000 volunteers who will have to answer a very simple questionnaire about their eating habits and provide a stool sample, 3 times over the course of a year.
